

10th January, 2018

Shortage of Anginine Aust R 227783 and Lycinate Aust R 227784 and alternative supply of GTN Glyceryl Trinitrate 300mcg tablets under Section 19A of the Therapeutic Goods Act 1989.

Dear Healthcare Professional,

HL Pharma Pty Ltd has been granted permission by the TGA to supply an alternative brand GTN glyceryl trinitrate 300mcg tablets, a UK licensed product, due to the unavailability of the Australian registered glyceryl trinitrate 600mcg tablets (Anginine AUSTR 227783 & Lycinate AUSTR 227784) in Australia under section 19A of the Therapeutic Goods Act 1989.

GTN glyceryl trinitrate 300mcg tablets is registered and marketed in the United Kingdom. This product is NOT registered in Australia.

GTN glyceryl trinitrate 300mcg tablets supplied by HL Pharma are HALF the strength of the Australian Registered products. Therefore, if a patient would normally use *half* a tablet of Anginine/Lycinate 600mcg, they should use *one* tablet of GTN 300mcg. Similarly, if a patient would normally use *one* tablet of Anginine/Lycinate 600mcg, they should use *two* tablets of GTN 300mcg.

Health professionals should carefully advise patients of the correct dose for their circumstances, noting this important difference.

The dosage of GTN may be repeated every 5 minutes for 15 minutes if symptoms are not relieved. If chest pain persists for more than 15 minutes, patients should seek medical advice immediately or call 000.

Glyceryl trinitrate is well absorbed through the buccal mucosa. It is therefore important that the tablets be placed under the tongue or in the cheek and allowed to dissolve rather than swallowed.

GTN, Anginine and Lycinate are all white and round in appearance. GTN glyceryl trinitrate 300mcg tablets are supplied in a blue, white and purple carton with an amber bottle inside whilst Anginine and Lycinate are supplied in an amber bottle with no carton.

Healthcare professionals and patients should be aware of the difference between these products to minimise medication errors.

Any adverse events which are experienced with GTN glyceryl trinitrate 300mcg tablets should be reported by healthcare professionals and patients to HL Pharma on 03 9823 6228, by email to contact@hlpharma.com.au , or to the TGA at: <https://www.tga.gov.au/reporting-problems>.

Please forward this information to relevant staff members in your organisation.

Any product complaints regarding GTN glyceryl trinitrate 300mcg tablets should be reported to HL Pharma by email contact@hlpharma.com.au or telephone 03 9823 6228.

Yours faithfully



Matt Hayward
Director BPharm, MRPharmS